This article is more than 5 years old. Information may no longer be current.
Top stories in endocrinology: FDA approves romosozumab for osteoporosis; Congressional hearing into 'broken system' behind insulin prices
Among the top stories in endocrinology last week were the FDA approving romosozumab to treat osteoporosis in postmenopausal women at high risk for fracture and the three manufacturers of insulin and the nation’s three largest pharmacy benefit managers testifying before Congress regarding the rising cost of insulin.
Other highlights included the FDA issuing a warning against the use of glucose test strips from a previous owner or test strips not authorized for sale in the U.S. because they may potentially cause infection or lead to inaccurate test results, research that indicated T-score is a 'key indicator' of fracture risk after long-term denosumab treatment and a study that found the average annual cost of diabetes for the entire U.S. population rose 13% between 2012 and 2017.
FDA approves romosozumab for osteoporosis
The FDA approved the monoclonal antibody romosozumab to treat osteoporosis in postmenopausal women at high risk for fracture, according to a press release from the agency. Read more.
Manufacturers, pharmacy benefit managers testify to 'broken system' behind high insulin prices
The three manufacturers of insulin and the nation’s three largest pharmacy benefit managers appeared together before Congress to respond to the growing outcry over the rising cost of insulin, at times blaming one another for high list prices that are putting a lifesaving drug out of reach for some people with diabetes. Read more.
FDA warns of health risks with 'pre-owned' glucose test strips
The FDA issued a warning against the use of test strips from a previous owner or test strips not authorized for sale in the U.S. because they may potentially cause infection or lead to inaccurate test results, according to a press release from the agency. Read more.
T-score 'key indicator' of fracture risk after long-term denosumab treatment
Most postmenopausal women with osteoporosis achieved a T-score above the osteoporosis threshold after receiving 10 years of denosumab therapy, with the incidence of nonvertebral fractures decreasing as a function of bone mineral density, according to findings published in the Journal of Bone and Mineral Research. Read more.
Diabetes creates 'hidden tax' for US residents
The average annual cost of diabetes for the entire U.S. population rose 13% between 2012 and 2017, according to findings presented in Diabetes Care. Read more.